These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29316377)

  • 21. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug.
    Kielhorn A; Porter D; Diamantopoulos A; Lewis G
    Curr Med Res Opin; 2008 Sep; 24(9):2639-50. PubMed ID: 18687164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis.
    Weycker D; Yu EB; Woolley JM; Oster G
    Clin Ther; 2005 May; 27(5):646-56. PubMed ID: 15978314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic burden of rheumatoid arthritis: a systematic review.
    Cooper NJ
    Rheumatology (Oxford); 2000 Jan; 39(1):28-33. PubMed ID: 10662870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis.
    Furneri G; Mantovani LG; Belisari A; Mosca M; Cristiani M; Bellelli S; Cortesi PA; Turchetti G
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S72-84. PubMed ID: 23072761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia].
    Mora C; González A; Díaz J; Quintana G
    Biomedica; 2009 Mar; 29(1):43-50. PubMed ID: 19753838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Societal costs of rheumatoid arthritis in China: a hospital-based cross-sectional study.
    Xu C; Wang X; Mu R; Yang L; Zhang Y; Han S; Li X; Wang Y; Wang G; Zhu P; Jin H; Sun L; Chen H; Cui L; Zhang Z; Li Z; Li J; Zhang F; Lin J; Liu X; Hu S; Yang X; Lai B; Li X; Wang X; Su Y; Li Z
    Arthritis Care Res (Hoboken); 2014 Apr; 66(4):523-31. PubMed ID: 24023001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
    Hamuryudan V; Direskeneli H; Ertenli I; Inanc M; Karaaslan Y; Oksel F; Ozbek S; Pay S; Terzioglu E; Balkan Tezer D; Hacibedel B; Akkoc N
    Clin Exp Rheumatol; 2016; 34(6):1033-1037. PubMed ID: 27749224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?
    Modena V; Bianchi G; Roccatello D
    Autoimmun Rev; 2013 Jun; 12(8):835-8. PubMed ID: 23219766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of-illness study.
    Zhu TY; Tam LS; Li EK
    Rheumatology (Oxford); 2011 Jul; 50(7):1293-301. PubMed ID: 21330341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline.
    Yelin E; Wanke LA
    Arthritis Rheum; 1999 Jun; 42(6):1209-18. PubMed ID: 10366114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicenter cost-of-illness study on rheumatoid arthritis in Italy.
    Leardini G; Salaffi F; Montanelli R; Gerzeli S; Canesi B
    Clin Exp Rheumatol; 2002; 20(4):505-15. PubMed ID: 12175106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medication adherence and cost-related medication non-adherence in patients with rheumatoid arthritis: A cross-sectional study.
    Heidari P; Cross W; Weller C; Nazarinia M; Crawford K
    Int J Rheum Dis; 2019 Apr; 22(4):555-566. PubMed ID: 30924291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Canadian estimates of health care utilization costs for rheumatoid arthritis patients with and without therapy with biologic agents.
    Ohinmaa AE; Thanh NX; Barnabe C; Martin L; Russell AS; Barr SG; Maksymowych WP
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1319-27. PubMed ID: 24470178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA.
    Tanaka E; Hoshi D; Igarashi A; Inoue E; Shidara K; Sugimoto N; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Tsutani K; Yamanaka H
    Mod Rheumatol; 2013 Jul; 23(4):742-51. PubMed ID: 22878927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
    Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
    J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.
    Cho SK; Lee J; Han M; Bae SC; Sung YK
    Arthritis Res Ther; 2017 Dec; 19(1):277. PubMed ID: 29246243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
    Khanna R; Smith MJ
    Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The economic burden of rheumatoid arthritis in a developing nation: results from a one-year prospective cohort study in Thailand.
    Osiri M; Maetzel A; Tugwell P
    J Rheumatol; 2007 Jan; 34(1):57-63. PubMed ID: 17183621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.